The impact of point-of-care testing and treatment of sexually transmitted infections and bacterial V aginosis on the genital epithelial barrier integrity.
Loading...
Date
2022
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
In sub-Saharan Africa, women and young girls suffer the highest burden of HIV infections.
Inflammation at the genital tract is a factor responsible for the increased susceptibility to HIV
risk in women, presumably through related epithelial barrier damage and target cell
recruitment. Considering the direct contribution of sexually transmitted infections (STIs) and
bacterial vaginosis (BV) to this inflammation, their effective treatment could potentially reduce
HIV risk in this vulnerable population. It has recently been shown in South African women
that a point-of-care (POC) STI/BV detection model, immediate treatment, and expedited
partner therapy (EPT) resolved STIs and reduced concentrations of genital proinflammatory
cytokines. This study investigated an additional impact of the model on the genital epithelial
barrier.
Methods
POC STI/BV screening was conducted on HIV-negative women (n=238) enrolled in the
CAPRISA 083 trial between May 2016 and June 2017. Chlamydia trachomatis and Neisseria
gonorrhoeae infections were detected by Xpert CT/NG test, while the OSOM Rapid test
detected Trichomonas vaginalis. Women were further tested for Mycoplasma genitalium and
BV using PCR and microscopy, respectively. Multiplex ELISA was used to quantify 48
cytokines and five matrix metalloproteinase (MMP) biomarkers of epithelial barrier integrity
from menstrual cup (MC) specimens (MMP-1, MMP-2, MMP-7, MMP-9, MMP-10). Mann-
Whitney U tests were used to assess the relationship between MMPs and STI/BV at baseline,
with ANOVA and multivariable linear mixed models used to determine the impact of treatment
on MMP concentrations.
Results
At baseline, women diagnosed with STI/BV (170/238) had higher concentrations of all MMPs
compared to women with neither STI/BV (68/238; p>0.05). Several proinflammatory and
chemotactic cytokine concentrations correlated significantly with that of MMPs at baseline. By
12 weeks post-treatment, 31/35 (88.57%) women resolved their baseline STIs, while only
14/57 (24.56%) resolved their baseline BV status. Most participants received concurrent
treatment for STIs and BV (n=60), with few receiving treatments for STI (n=3) or BV alone15
(n=25). Significant reductions in MMP-1 concentrations were observed after 6 weeks in
women treated for STI and BV (2.763 pg/ml; p= 0.0066) or STIs regardless of BV status (2.760
pg/ml; p= 0.0048). No changes in MMP concentrations were observed in women treated for BV.
Conclusion
POC STI/BV treatment was associated with a reduction in MMP-1 concentrations. This
implies that although POC STI/BV treatment may treat STIs and reduce inflammation, the
integrity of the genital epithelial barrier may not be fully restored, and women remain
susceptible to genital infections, including HIV, as a result. Additional strategies may be
needed to repair the genital epithelium after treatment.
Description
Masters Degree. University of KwaZulu-Natal, Durban.